170 related articles for article (PubMed ID: 36619548)
1. Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations.
Whitmer D; Phay JE; Holt S; O'Donnell B; Nguyen J; Joseph D; Chi A; Wu S; Hao Y; Huang J; Klopper JP; Kloos RT; Kennedy GC; Shin J
Front Endocrinol (Lausanne); 2022; 13():1073592. PubMed ID: 36619548
[TBL] [Abstract][Full Text] [Related]
2. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
Yang Z; Zhang T; Layfield L; Esebua M
J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of cancer and the benign call rate of afirma gene classifier in
Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
[TBL] [Abstract][Full Text] [Related]
4. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
[No Abstract] [Full Text] [Related]
5. Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.
Polavarapu P; Fingeret A; Yuil-Valdes A; Olson D; Patel A; Shivaswamy V; Matthias TD; Goldner W
J Endocr Soc; 2021 Nov; 5(11):bvab148. PubMed ID: 34708178
[TBL] [Abstract][Full Text] [Related]
6. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
[No Abstract] [Full Text] [Related]
7. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
8. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
9. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
10. STATISTICAL COMPARISON OF AFIRMA GSC AND AFIRMA GEC OUTCOMES IN A COMMUNITY ENDOCRINE SURGICAL PRACTICE: EARLY FINDINGS.
Harrell RM; Eyerly-Webb SA; Golding AC; Edwards CM; Bimston DN
Endocr Pract; 2019 Feb; 25(2):161-164. PubMed ID: 30383497
[TBL] [Abstract][Full Text] [Related]
11. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
Wei S; Veloski C; Sharda P; Ehya H
Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
[TBL] [Abstract][Full Text] [Related]
12. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations.
Mon SY; Riedlinger G; Abbott CE; Seethala R; Ohori NP; Nikiforova MN; Nikiforov YE; Hodak SP
Diagn Cytopathol; 2018 May; 46(5):369-377. PubMed ID: 29516685
[TBL] [Abstract][Full Text] [Related]
14. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
Geng Y; Aguilar-Jakthong JS; Moatamed NA
Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
[TBL] [Abstract][Full Text] [Related]
16. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
17. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis.
Nasr CE; Andrioli M; Endo M; Harrell RM; Livhits MJ; Osakwe I; Polavarapu P; Siperstein A; Wei S; Zheng X; Jiang R; Hao Y; Huang JIN; Klopper JP; Kloos RT; Kennedy G; Angell TE
J Clin Endocrinol Metab; 2023 May; 108(6):1526-1532. PubMed ID: 36470585
[TBL] [Abstract][Full Text] [Related]
18. Analytical Verification Performance of Afirma Genomic Sequencing Classifier in the Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Hao Y; Choi Y; Babiarz JE; Kloos RT; Kennedy GC; Huang J; Walsh PS
Front Endocrinol (Lausanne); 2019; 10():438. PubMed ID: 31333584
[No Abstract] [Full Text] [Related]
19. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
Harrison G; Sosa JA; Jiang X
Arch Pathol Lab Med; 2017 Jul; 141(7):985-989. PubMed ID: 28467214
[TBL] [Abstract][Full Text] [Related]
20. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
